然而，长期以来，da Vinci 机器人系列几乎垄断了机器人手术市场。直到 2019 年，创新的手术平台开始进入市场，其中 Medtronic Hugo TM RAS 在 2021 年获得欧盟批准，截至 2024 年 7 月，已有 100 个平台安装并开展了超过 10000 例手术 。但关于该新平台在妇科手术中的应用 ...

Medtronic is nearing a U.S. launch for its Hugo surgical robot more than three years after receiving approval to release the soft tissue system in Europe. CEO Geoff Martha told investors Tuesday ...

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how ...

Medtronic’s potential rivalry in US market Medtronic’s Hugo robot poses the main challenge to da Vinci given the company's size. Hugo has been in use in Europe since 2022 and the company ...

Intuitive remains the dominant surgical robotics company — but other companies with savvy strategies are generating buzz and ...

Discover why Intuitive Surgical's monopoly-like position is under threat from emerging competitors like Medtronic and J&J.

2. Renal denervation: Medtronic is awaiting CMS approval for this innovative treatment, which could open up new revenue streams in the hypertension market. 3. Hugo surgical robot: The company’s ...

2. Renal denervation: Medtronic is awaiting CMS approval for this innovative treatment, which could open up new revenue streams in the hypertension market. 3. Hugo surgical robot: The company’s entry ...